ASH Clinical News Advances in Hematology Research & Patient Care: Hi | Page 8

IMBRUVICA® (ibrutinib) capsules

IMBRUVICA® (ibrutinib) capsules

Table 6: Treatment-Emergent* Decrease of Hemoglobin, Platelets,
or Neutrophils in Study 2

Neutrophils Decreased
Platelets Decreased
Hemoglobin Decreased

IMBRUVICA
(N=195)
Grade
All
3 or 4
Grades
(%)
(%)
51
23
52
5
36
0

Ofatumumab
(N=191)
Grade
All
3 or 4
Grades
(%)
(%)
57
26
45
10
21
0

* Based on laboratory measurements per IWCLL criteria
Waldenström’s Macroglobulinemia
The data described below reflect exposure to IMBRUVICA in an open label
clinical trial that included 63 patients with previously treated WM.
The most commonly occurring adverse reactions in the WM trial (≥ 20%) were
neutropenia, thrombocytopenia, diarrhea, rash, nausea